# Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

> **NCT05346666** · PHASE3 · UNKNOWN · sponsor: **Damanhour University** · enrollment: 50 (estimated)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Tocilizumab Prefilled Syringe [Actemra]. propofole, phenobarbital, midazolam

## Key facts

- **NCT ID:** NCT05346666
- **Lead sponsor:** Damanhour University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-25
- **Primary completion:** 2023-09-20
- **Final completion:** 2023-10-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05346666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05346666, "Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05346666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*